Ernexa Therapeutics Inc. (ERNA) News
Follow Ernexa Therapeutics Inc. (ERNA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Ernexa Therapeutics (ERNA) Reports Clean IND-Enabling Safety Data, Targets Q4 2026 IND
Ernexa Therapeutics reported favorable repeat-dose tox, tumorigenicity and biodistribution results for ERNA-101 and said GMP manufacturing is underway, with an IND submission planned for Q4 2026 for platinum-resistant ov
NEWS | Sep 30, 2026, 12:38 PM UTC
L
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute c
NEWS | Sep 30, 2026, 12:38 PM UTC
L
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sectorPresident & CEO Sanjeev Luther to deliver an Innovation Spotlight presentation on October 6, 20
NEWS | Sep 29, 2026, 01:18 PM UTC
L
Ernexa Therapeutics appoints Robert J. Spiegel to board
Ernexa Therapeutics appointed Robert J. Spiegel, M.D., FACP, to its Board of Directors as it advances ERNA-101 toward clinical development.
EQUITY | Sep 17, 2026, 12:51 PM UTC
L
ERNA - Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
ERNA - Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
NEWS | Sep 17, 2026, 12:42 PM UTC
L
Ernexa Therapeutics (NASDAQ:ERNA) Prioritizes ERNA-101; ERNA-201 Shows Preclinical Signal
Ernexa will concentrate resources on advancing ERNA-101 toward a planned IND in Q4 2026, after ERNA-201 showed preliminary disease-modifying activity in a collagen-induced arthritis model. ERNA-201 spend is paused; initi
NEWS | Sep 15, 2026, 12:51 PM UTC
L
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC platform beyond oncolog
NEWS | Sep 15, 2026, 12:51 PM UTC
L
ERNA - Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
ERNA - Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
NEWS | Sep 15, 2026, 12:42 PM UTC
L
ERNA - Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
ERNA - Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
EQUITY | Aug 27, 2026, 01:02 PM UTC
L
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
EQUITY | Aug 27, 2026, 01:01 PM UTC
H
Dow Gains Over 150 Points; Morgan Stanley Profit Tops Views
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 150 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.31% to 52,670.85 while the NASDAQ rose 0.71% to 26,291.06
CENTRAL_BANK | Jul 15, 2026, 01:43 PM UTC
L
ERNA Ernexa Therapeutics - on track for ind submission Q3 2026 and phase 1 trial Q4 2026 - Plans ind submission for Q3 2026; phase 1 trial e
ERNA Ernexa Therapeutics - on track for ind submission Q3 2026 and phase 1 trial Q4 2026 - Plans ind submission for Q3 2026; phase 1 trial expected to begin Q4 2026 - Erna-101 plus anti-pd-1 achieves complete tumor clear
EQUITY | Jul 15, 2026, 11:54 AM UTC
L
ERNA Ernexa Therapeutics CEO corner highlights differentiated erna-101 platform as company advances toward planned first-in-human phase 1 st
ERNA Ernexa Therapeutics CEO corner highlights differentiated erna-101 platform as company advances toward planned first-in-human phase 1 study in 2026
EQUITY | Jul 14, 2026, 01:02 PM UTC